Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (19402)	3/22/2006 1:04:21 AM
From: zeta1961	Respond to of 52153

I think it's helpful to remember that it takes years for the successful p2 drug to get to the patient..using telcyta as an example because its shown strong activity in p1/p2, there's no way I'd participate in P3 unless I knew I'd get the active drug[it's this issue that most makes these trials drag on]..stretching to p3's in the salvage setting is unacceptable, imo..surely we can design a better way for this population to get drug if they want it.. Elisabeth